{"id":1906,"date":"2013-10-26T10:05:25","date_gmt":"2013-10-26T10:05:25","guid":{"rendered":"http:\/\/people.unica.it\/molecularmedicine\/?page_id=1906"},"modified":"2023-06-20T08:22:36","modified_gmt":"2023-06-20T08:22:36","slug":"clelia-madeddu","status":"publish","type":"page","link":"https:\/\/people.unica.it\/molecularmedicine\/faculty\/molecular-oncology-and-pathology\/clelia-madeddu\/","title":{"rendered":"Clelia Madeddu"},"content":{"rendered":"

Department of Medical Sciences ‘M. Aresu’<\/span><\/p>\n

Telephone: +39 0706754228<\/span><\/p>\n

E-mail: <\/span>clelia_md@yahoo.it<\/a><\/span><\/span>
\n<\/a><\/p>\n

Personal webpage:<\/span> here<\/span><\/span><\/a><\/p>\n

Main areas of expertise: Molecular pathology; Oncology<\/span><\/p>\n

 <\/p>\n

\n

\u2666 Tissue microenvironment and tumoral microenvironment in the carcinogenic process. Prognostic and diagnostic molecular markers correlated to cancer cell biology, cell metabolism, cell cycle regulation, and cancer progression<\/span><\/span><\/p>\n

Cancer progression is characterized by specific molecular and metabolic changes, which play a central role in the pathogenesis of patients\u2019 symptoms and disease outcome. In particular, inflammatory mediators, synthesized by tumor and immune cells, are involved in the regulation of molecular pathways driving tumor progression at tumor microenvironment. Moreover, they act also at systemic levels on different peripheral and central sites and influence the molecular and metabolic pathways involved in the pathogenesis of cancer symptoms. A better knowledge of these changes may allow to develop new and targeted drugs able to counteract cancer progression as well as patient symptoms. Our laboratory is experienced in translational research, which ranges from the evaluation of these mechanisms in in vivo and in vitro systems to the assessment of these molecular pathways and their modulation by targeted specific treatments in cancer patients.<\/span><\/p>\n

Within this general line of research, specific projects are:<\/span><\/p>\n

    \n
  1. Molecular mechanisms linking inflammation and immune system response with cancer development and progession<\/span><\/li>\n
  2. Molecular factors involved in the pathogenesis and prognosis of ovarian cancer<\/span><\/li>\n
  3. Molecular and biological mediators involved in the pathogenesis of cancer-related symptoms and their role as target of personalized targeted treatment<\/span><\/li>\n
  4. Role of leptin in the pathogenesis of endocrine-related cancer and metabolic disorders in cancer patients<\/span><\/li>\n
  5. Oxidative stress and cancer. Role in carcinogenesis, tumor progression, and pathogenesis of cancer-related symptoms and antineoplastic treatment toxicities.<\/span><\/li>\n<\/ol>\n
    \n

    Key publications:<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C (2013) The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-a review. J Mol Med (Berl)<\/em>, doi: 10.1007\/s00109-013-1080-7<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C (2013) Cisplatin: an old drug with a newfound efficacy — from mechanisms of action to cytotoxicity. Expert Opin Pharmacother <\/i>14<\/b>: 1839-1857<\/span><\/p>\n

    Mantovani G, Madeddu C, Macci\u00f2 A (2013) Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Des Devel Ther<\/i> 7<\/b>: 645-656<\/span><\/p>\n

    Mantovani G, Madeddu C, Macci\u00f2 A (2012) Cachexia and oxidative stress in cancer: an innovative therapeutic management. Curr Pharm Des<\/i> 18<\/b>: 4813-4818<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine<\/i> 58<\/b>: 133-147<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G (2010) Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl)<\/i> 88<\/b>: 677-686<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C, Mantovani G (2009) Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev <\/i>10<\/strong>: 660-670<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C, Massa D, Astara G, Farci D, Melis GB, Mantovani G (2009) Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med<\/i> 13<\/b>: 3951-3919<\/span><\/p>\n

    Mantovani G, Macci\u00f2 A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia\/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev<\/i> 15<\/b>: 1030-1034<\/span><\/p>\n

    Macci\u00f2 A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G (2005) Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood <\/i>106<\/b>: 362-367<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

    Department of Medical Sciences ‘M. Aresu’ Telephone: +39 0706754228 E-mail: clelia_md@yahoo.it Personal webpage: here Main areas of expertise: Molecular pathology; Oncology   \u2666 Tissue microenvironment and tumoral microenvironment in the carcinogenic process. Prognostic and diagnostic molecular markers correlated to cancer cell biology, cell metabolism, cell cycle regulation, and cancer progression Cancer progression is characterized by specific molecular and metabolic changes, which play a central role in the pathogenesis of patients\u2019 symptoms and disease outcome. In particular, inflammatory mediators, synthesized by tumor and immune cells, are involved in the regulation of molecular pathways driving tumor progression at tumor microenvironment. Moreover, they act also […]<\/a><\/p>\n","protected":false},"author":2009,"featured_media":0,"parent":1658,"menu_order":7,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-1906","page","type-page","status-publish","hentry","post-seq-1","post-parity-odd","meta-position-corners","fix"],"_links":{"self":[{"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/pages\/1906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/users\/2009"}],"replies":[{"embeddable":true,"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/comments?post=1906"}],"version-history":[{"count":15,"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/pages\/1906\/revisions"}],"predecessor-version":[{"id":3423,"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/pages\/1906\/revisions\/3423"}],"up":[{"embeddable":true,"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/pages\/1658"}],"wp:attachment":[{"href":"https:\/\/people.unica.it\/molecularmedicine\/wp-json\/wp\/v2\/media?parent=1906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}